title: [Chemotherapy of brain tumors in aduts].
abstract: The treatment of patients with brain tumors has long been the domain of neurosurgery and radiotherapy but chemotherapy is now well established as an additional treatment option for many tumor entities in neuro-oncology. This is particularly true for patients with newly diagnosed and relapsing glioblastoma and anaplastic glioma as well as the treatment of medulloblastoma and primary lymphoma of the central nervous system (CNS). In addition to purely histopathological features, treatment decisions including those for chemotherapy are now based increasingly more on molecular tumor profiling. Within the group of gliomas these markers include the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter and the 1p/19q status, which reflects the loss of genetic material on chromosome arms 1p and 19q. The presence of a 1p/19q codeletion is associated with a better prognosis and increased sensitivity to alkylating chemotherapy in patients with anaplastic gliomas.
authors.affiliation: Klinik für Neurologie und Hirntumorzentrum, UniversitätsSpital Zürich, Frauenklinikstr. 26, 8091, Zürich, Schweiz, patrick.roth@usz.ch.
authors.forename: P
authors.initials: P
authors.lastname: Roth
authors.forename: M
authors.initials: M
authors.lastname: Weller
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008297:Male; D018579:Patient Selection
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor